“Biotech company Ultimovacs continues to strengthen the clinical evidence for its universal cancer vaccine UV1. On Wednesday morning the company could announce positive results from a phase I study of UV1 in combination with the checkpoint inhibitor pembrolizumab. The combination, which was tested in patients with metastatic malignant melanoma, showed the very encouraging survival rate of 80 per cent after 24 months.”
Read the full article here